{"id":532197,"date":"2021-03-01T17:16:01","date_gmt":"2021-03-01T17:16:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=532197"},"modified":"2021-03-01T17:16:01","modified_gmt":"2021-03-01T17:16:01","slug":"acute-renal-failure-arf-acute-kidney-injury-market-insights-epidemiology-and-market-forecast-2030-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acute-renal-failure-arf-acute-kidney-injury-market-insights-epidemiology-and-market-forecast-2030-by-delveinsight_532197.html","title":{"rendered":"Acute Renal Failure (ARF) (Acute Kidney Injury) Market Insights, Epidemiology, and Market Forecast 2030 by DelveInsight"},"content":{"rendered":"
\"Acute<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Acute Renal Failure (ARF) (Acute Kidney Injury) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Acute Renal Failure (ARF) (Acute Kidney Injury), historical and forecasted epidemiology as well as the Acute Renal Failure (ARF) (Acute Kidney Injury) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight launched a new report on Acute Renal Failure Market Insights, Epidemiology, and Market Forecast 2030<\/strong><\/a>.<\/p>\n

DelveInsight’s “Acute Renal Failure (ARF) (Acute Kidney Injury) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>” report delivers an in-depth understanding of the Acute Renal Failure (ARF) (Acute Kidney Injury), historical and forecasted epidemiology as well as the Acute Renal Failure (ARF) (Acute Kidney Injury) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

\"\"<\/p>\n

Acute Renal Failure, which is now known as Acute Kidney Injury is characterized by azotemia that progresses over several hours or days, with or without oliguria. ARF is commonly defined as an abrupt decline in renal function, clinically manifesting as a reversible acute increase in nitrogen waste products measured by blood urea nitrogen (BUN) and serum creatinine levels over the course of hours to weeks. The disease leads to an abrupt loss of kidney function, leading to the retention of waste products, electrolyte disturbances, and volume status changes. <\/p>\n

Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/acute-renal-failure-arf-acute-kidney-injury-market<\/span><\/a><\/strong><\/p>\n

Acute kidney injury (AKI) is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a build-up of waste products in your blood and makes it hard for your kidneys to keep the right balance of fluid in your body.<\/p>\n

Robust pipeline with a novel mechanism of action and increasing incidence are major market drivers of Acute Kidney Injury market. Additionally, the Acute Kidney Injury pipeline is also expected to change the current dynamics of market which presently comprises of Biologics and molecules with new mechanisms of action.<\/p>\n<\/div>\n

\n
The risk factors associated with AKI include age, exposure to nephrotoxins, family history, race and ethnicity, gender and other factors.<\/div>\n
 <\/div>\n
Of the emerging therapies for AKI, the key players include ANG-3777 (BB3; Angion Biomedica), QPI1002 (Quark Pharmaceutical), ASP1128 (Astellas Pharma), MB-102 (MediBeacon), Ruconest (Conestat alfa; PharmingTechnologies), recAP (AM Pharma), bRESCAP (Alloksys), EA-230 (Exponential Biotherapies) and Simdax (Levosimendan; Orion Pharma). <\/div>\n
\n

Click here and get access to free sample pages.<\/strong><\/a><\/p>\n

Scope of the Report<\/strong><\/p>\n